Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YS001
- Development stage
- Phase 1
- Lead developer
- Suzhou Zerun New Drug Development
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
YS001 is an orally bioavailable small molecule dual inhibitor of Phosphatidylinositol 3-kinase (PI3K) and the mechanistic target of rapamycin (mTOR). Developed by JiangSu WuZhong Pharmaceutical Development in collaboration with Zerun New Drug R&D and a technology team from the Zhejiang University School of Pharmacy, it is designed to treat advanced malignant solid tumors by inhibiting the PI3K/AKT/mTOR signaling pathway, which is frequently dysregulated in various cancers. The drug is currently in Phase 1 clinical development, having completed dose-escalation studies to evaluate its safety, tolerability, and pharmacokinetics in patients with advanced solid tumors.
- Other names
- YS001 capsuleYS-001 capsuleYS 001 capsuleYS001胶囊肿瘤治疗创新药YS001胶囊
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)Mechanistic target of rapamycin complex 1Mechanistic target of rapamycin kinase complex 2
Beyond the preview
Go deeper on YS001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YS001.